Evolving Role of Oral Chemotherapy for the Treatment of Patients with Neoplasms

ONCOLOGY

Volumn 12, Issue 3 SUPPL. 4, 1998, Pages 43-50

  Anthony Greco, F ^a  

^a Sarah Cannon Minnie Pearl Cancer C   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE SODIUM; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; HYDROXYUREA; MEGESTROL ACETATE; METHOTREXATE; PLATINUM DERIVATIVE; PREDNISONE; PROCARBAZINE; PYRIMIDINE DERIVATIVE; TAMOXIFEN; TAMOXIFEN CITRATE; VINCRISTINE; VINCRISTINE SULFATE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT CARE; PRACTICE GUIDELINE; REVIEW;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HUMANS; PRACTICE GUIDELINES;

EID: 0031960169     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Edwards CM, Glisson BS, King CK, et al: Etoposide-induced DNA cleavage in human leukemia cells. Cancer Chemother Pharmacol 20:162-168, 1987
2. Sullivan DM, Chow KC, Glisson BS, et al: Role of proliferation in determining sensitivity to topoisomerase II-active chemotherapy agents. NCI Monogr 4:73-78, 1987.
3. Dombernowsky P, Nissen NI: Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP16-213 (NSC-141540) in L1210 leukemia Acta Pathol Microbiol Scand 81:715-724, 1973.
4. D'Incalci M, Eiba E, Vaghi M, et al: In vitro cytotoxicity of VP16 on primary tumor and metastasis of Lewis lung carcinoma. Eur J Cancer Clin Oncol 18:377-380, 1982.
5. Cavalli F, Sonntag RW, Jungi F, et al. VP16-213 monotherapy for remission induction of small-cell-lung cancer: A randomized trial using three dosage schedules. Cancer Treat Rep 62:473-475, 1978.
6. Slevin ML, Clark PI, Osborne RJ, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333-1340, 1990.
7. Hainsworth JD, Johnson DH, Frazier SR, et al: Chronic administration of oral etoposide: A phase I trial. J Clin Oncol 7.396-401, 1989.
8. Hande KR, Krozely MG, Greco FA, et al: Unavailability of low-dose oral etoposide. J Clin Oncol 11:374-377, 1993.
9. Johnson DH, Greco FA, Strupp J, et al: Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: A phase II trial. J Clin Oncol 8:1613-1617, 1990
10. Clark PI, Cottier B: The activity of 10-, 14-, and 21-day schedules of single-agent etoposide in previously untreated patients with extensive small cell lung cancer. Semin Oncol 19(suppl 14):36-39, 1992.
11. Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small-cell lung cancer: A phase II trial J Clin Oncol 10:292-296, 1992.
12. Saman S, Logie B, Stephens D, et al: Phase II trial of daily oral etoposide in patients with surgically unresectable non-small cell lung cancer, Invest New Drugs 9.253-256, 1991.
13. Miller AA, Tolley EA, Niell HB, et al: Pharmacokinetics of prolonged oral etoposide in patients with advanced non-small-cell lung cancer J Clin Oncol 11:1179-1188, 1993.
14. Hainsworth JD, Johnson DH, Frazier SR, et al: Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 26.18-821, 1990.
15. Garrow GC, Hainsworth JD, Johnson DH, et al: Prolonged administration of oral etoposide in previously treated epithelial ovarian cancer: A phase II trial (abstract). Proc Am Soc Clin Oncol 11.236, 1992.
16. Hoskins PJ, Swenerton KD Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60-63, 1994
17. Marzola M, Zucchetti M, Colombo N, et al: Low dose oral etoposide in epithelial cancer of the ovary Ann Oncol 4:517-519, 1993.
18. Calvert AH, Lind MJ, Millward MM, et al. Long-term oral etoposide in metastatic breast cancer. Clinical and pharmacokinetic results Cancer Trent Rev 19 (suppl C):27-33, 1993.
19. Martin M, Lluch A, Casado A, et al: Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 12:986-991, 1994.
20. Miller JC, Einhorn LH: Phase II study of daily oial etoposide in refractory germ cell tumors. Semin Oncol 17(suppl 2):36-39, 1990.
21. Smit EF, Sutedja T, van Zandwijk N, et al: A phase II study of daily oral etoposide for 21 days q 5 weeks in malignant mesothelioma. Proc Eur Conf Clin Oncol 6:171, 1991.
22. Ajani J, Dimas P, Pazdur R, et al: Phase II trial of oral etoposide in untreated patients with advanced gastric carcinoma (abstract). Proc Am Soc Clin Oncol 12:217, 1993.
23. Kampe CE, Lowenbraun S, Foster J, et al: Oral etoposide in treatment of advanced refractory sarcomas J Natl Cancer Inst 84:1836-1837, 1992.
24. Wierzbicki R, Ezzat A, Abdel-Warith A, et al. Phase II trial of chronic daily VP-16 administration in unresectable hepatocellular carcinoma. Ann Oncol 5.466-467, 1994.
25. Cooper MA, Einhorn LH: Maintenance chemotherapy with daily oral etoposide following salvage therapy in patients with germ cell tumors. J Clin Oncol 13:1167-1169, 1995.
26. Murphy PB, Hainsworth JD, Greco FA, et al: A phase II trial of cisplatin and prolonged administration of oral etoposide in extensive-stage small cell lung cancer. Cancer 69-370-374, 1992.
27. Johnson DH, Hainsworth JD, Devore R, et al: Carboplatin plus oral etoposide in the management of unresectable non-small-cell lung cancer: Preliminary results of a Vanderbilt trial. Oncology 49(suppl l):57-62, 1992.
28. Miller AA, Herndon JE, Hollis DR, et al: Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small cell lung cancer: A randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 13:1871-1879, 1995.
29. Faylona EA, Loehrer PJ, Ansari R, et al: Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: A Hoosier Oncology Group trial. J Clin Oncol 13:1209-1214, 1995.
30. Grunberg SM, Crowley J, Livingston R, et al: Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 11:1598-1601, 1993.
31. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994.
32. Young WA, Greco FA, Greer JP, et al: Aggressive non-Hodgkin's lymphoma in the eld- erly: An effective, well-tolerated treatment regimen containing extended-schedule etoposide. J Natl Cancer Inst 86:1346-1347, 1994.
33. Bonadonna G: Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res 52:2127-2137, 1992.
34. Cooper RG: Adjuvant chemotherapy for breast cancer. 20 years' experience using CVFMP chemotherapy. Semin Oncol 15(suppl 3):29-34, 1988.
35. Ozer H, Anderson JR, Peterson BA, et al: Combination trial of subcutaneous recombinant alpha 2b interferon and oral cyclophosphamide in follicular low-grade lymphoma. Med Pediatr Oncol 22:228-235, 1994.